SCHEMBL6548424

SCHEMBL6548424

COC(=O)c1ccccc1Cn1c(N)nc2ncn(Cc3ccc4ccccc4c3)c2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 2/20 0.40
GAA P10253 1/20 0.40
DPP4 P27487 1/20 0.37
LMNA P02545 1/20 0.37
NPBWR1 P48145 1/20 0.37
SIRT2 Q8IXJ6 1/20 0.37
ADORA2A P29274 1/20 0.36
ALDH1A1 P00352 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TRPA1 O75762 1/20 0.36
MAPT P10636 1/20 0.36
KLKB1 P03952 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
IDO1 P14902 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6800743 0.88 LMNA (0.48) TLR7GAALMNASMN1; SMN2MAPT
SCHEMBL6550804 0.88 LMNA (0.48) TLR7GAALMNASMN1; SMN2MAPT
SCHEMBL7115497 0.86 TLR7 (0.42) TLR7DPP4NPBWR1SIRT2ADORA2A
SCHEMBL6549292 0.86 IDO1 (0.49) TLR7GAALMNAADORA2AMAPT
SCHEMBL6797064 0.84 GAA (0.43) GAADPP4SIRT2ADORA2AALDH1A1
SCHEMBL6548972 0.80 GAA (0.41) GAALMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL6549145 0.79 GAA (0.52) GAAALDH1A1SMN1; SMN2TRPA1MAPT
SCHEMBL6550714 0.78 LMNA (0.52) TLR7GAALMNAALDH1A1SMN1; SMN2
SCHEMBL6801426 0.78 MCHR1 (0.39) GAAADORA2AALDH1A1SMN1; SMN2TRPA1
SCHEMBL6796275 0.78 KMT2A (0.47) GAALMNAALDH1A1SMN1; SMN2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1383766-A1 DISUBSTITUTED 1,7-GUANINES Pharmacia Italia S.p.A. (IT) 2004-01-28 EP claimed
WO-2002090357-A1 DISUBSTITUTED 1,7-GUANINES PHARMACIA ITALIA S.P.A. (IT) 2002-11-14 WO claimed
US-20040138212-A1 Disubstituted 1,7-guanines PHARMACIA ITALIA, S.P.A. (IT) 2004-07-15 US disclosed
EP-1383766-A1 DISUBSTITUTED 1,7-GUANINES Pharmacia Italia S.p.A. (IT) 2004-01-28 EP disclosed
WO-2002090357-A1 DISUBSTITUTED 1,7-GUANINES PHARMACIA ITALIA S.P.A. (IT) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138212-A1 Disubstituted 1,7-guanines GDA, UNG, TYMS TLR7 1374/4885GAA 404/4885DPP4 3275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.